nach oben

Neurological Sciences

Erschienen in:

25.08.2023 | Original Article

The relationship between plasma prolactin levels and clinical manifestations with neuromyelitis optica spectrum disorders

verfasst von: Hanchen Liu, Xianxing Zhang, Wei Chen, Yiwen Xu, Xiaoting Lin, Aiyu Lin

Erschienen in: Neurological Sciences | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Systemic prolactin levels have been found to increase in 19 patients diagnosed with neuromyelitis optica spectrum disorders (NMOSD). However, the relationship between plasma prolactin levels and clinical manifestations in NMOSD patients remains unclear.

Methods

This cross-sectional study was conducted as part of a Registered Cohort Study of Inflammatory Demyelination Disease (NCT04386018). A total of 95 patients diagnosed with central nervous system demyelinating diseases and 43 healthy controls were recruited between May 2020 and February 2022 at the First Affiliated Hospital of Fujian Medical University. Plasma samples were collected from all participants and analyzed for prolactin levels using electrochemiluminescence immunoassay. The study aimed to investigate the correlation between plasma prolactin levels and clinical features in patients with central nervous system demyelinating diseases.

Results

Plasma prolactin levels in NMOSD patients were significantly higher than those in multiple sclerosis/myelin oligodendrocyte glycoprotein antibody–associated diseases patients and controls (p<0.05, respectively), and were found to be correlated with disease activity, sensory abnormalities, thoracic spinal cord lesions, and MR lesion enhancement (p<0.05). A total of 16.28% of NMOSD patients exhibited macroprolactinemia. However, there was no correlation found between macroprolactin levels and disease activity (p>0.05).

Conclusion

Prolactin may play a role in the pro-inflammatory regulation mechanism of NMOSD.

Bove R, Elsone L, Alvarez E et al (2017) Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm 4(3):e339. https://doi.org/10.1212/NXI.0000000000000339CrossRefPubMedPubMedCentral

Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189. https://doi.org/10.1212/wnl.0000000000001729CrossRefPubMedPubMedCentral

Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. https://doi.org/10.1186/1742-2094-9-14CrossRefPubMedPubMedCentral

Pandit L, Asgari N, Apiwattanakul M et al (2015) Demographic and clinical features of neuromyelitis optica: a review. Multiple Scler (Houndmills, Basingstoke, England) 21(7):845–853. https://doi.org/10.1177/1352458515572406CrossRef

Banwell B, Marrie RA (2017) Increased relapse rate during pregnancy and postpartum in neuromyelitis optica. Neurology 89(22):2220–2221. https://doi.org/10.1212/wnl.0000000000004721CrossRefPubMed

Collongues N, Alves Do Rego C, Bourre B et al (2021) Pregnancy in patients with AQP4-Ab, MOG-Ab, or double-negative neuromyelitis optica disorder. Neurology 96(15):e2006–e2015. https://doi.org/10.1212/wnl.0000000000011744CrossRefPubMed

Klawiter EC, Bove R, Elsone L et al (2017) High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology 89(22):2238–2244. https://doi.org/10.1212/wnl.0000000000004681CrossRefPubMedPubMedCentral

Langer-Gould A, Smith JB, Albers KB et al (2020) Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology 94(18):e1939–e1949. https://doi.org/10.1212/wnl.0000000000009374CrossRefPubMedPubMedCentral

Borba VV, Zandman-Goddard G, Shoenfeld Y (2019) Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best Pract Res Clin Endocrinol Metab 33(6):101324. https://doi.org/10.1016/j.beem.2019.101324CrossRefPubMed

10.

Vilar L, Vilar CF, Lyra R, Freitas MDC (2019) Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology 109(1):7–19. https://doi.org/10.1159/000499694CrossRefPubMed

11.

Gregg C (2009) Pregnancy, prolactin and white matter regeneration. J Neurol Sci 285(1-2):22–27. https://doi.org/10.1016/j.jns.2009.06.040CrossRefPubMed

12.

Cabrera-Reyes EA, Limón-Morales O, Rivero-Segura NA, Camacho-Arroyo I, Cerbón M (2017) Prolactin function and putative expression in the brain. Endocrine 57(2):199–213. https://doi.org/10.1007/s12020-017-1346-xCrossRefPubMed

13.

Gregg C, Shikar V, Larsen P et al (2007) White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci : Offl J Soc Neurosci 27(8):1812–1823. https://doi.org/10.1523/jneurosci.4441-06.2007CrossRef

14.

Shelly S, Boaz M, Orbach H (2012) Prolactin and autoimmunity. Autoimmun Rev 11(6-7):A465–A470. https://doi.org/10.1016/j.autrev.2011.11.009CrossRefPubMed

15.

Türkoğlu R, Giriş M, Gencer M, Akcan U, Örçen A (2016) Serum prolactin levels in multiple sclerosis, neuromyelitis optica, and clinically isolated syndrome patients. Noro Psikiyatr Ars 53(4):353–356. https://doi.org/10.5152/npa.2016.16979CrossRefPubMedPubMedCentral

16.

Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134. https://doi.org/10.1186/s12974-018-1144-2CrossRefPubMedPubMedCentral

17.

López-Chiriboga AS, Majed M, Fryer J et al (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 75(11):1355–1363. https://doi.org/10.1001/jamaneurol.2018.1814CrossRefPubMedPubMedCentral

18.

Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22(3):268–282. https://doi.org/10.1016/S1474-4422(22)00431-8CrossRefPubMed

19.

Kim Y, Hyun JW, Woodhall MR et al (2020) Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. Mult Scler Relat Disord 40:101939. https://doi.org/10.1016/j.msard.2020.101939CrossRefPubMed

20.

Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/s1474-4422(17)30470-2CrossRefPubMed

21.

Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692CrossRefPubMed

22.

Sepulveda M, Delgado-García G, Blanco Y et al (2019) Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurol(R) Neuroimmunol Neuroinflamm 6(6). https://doi.org/10.1212/NXI.0000000000000607

23.

Kasum M, Pavičić-Baldani D, Stanić P et al (2014) Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 183:28–32. https://doi.org/10.1016/j.ejogrb.2014.10.013CrossRefPubMed

24.

Fahie-Wilson M, Brunsden P, Surrey J, Everitt A (2000) Macroprolactin and the Roche Elecsys prolactin assay: characteristics of the reaction and detection by precipitation with polyethylene glycol. Clin Chem 46(12):1993–1995. https://doi.org/10.1093/clinchem/46.12.1993CrossRefPubMed

25.

Fahie-Wilson M, Smith TP (2013) Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab 27(5):725–742. https://doi.org/10.1016/j.beem.2013.07.002CrossRefPubMed

26.

Fahie-Wilson M (2003) In hyperprolactinemia, testing for macroprolactin is essential. Clin Chem 49(9):1434–1436CrossRefPubMed

27.

Bernard V, Young J, Binart N (2019) Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol 15(6):356–365. https://doi.org/10.1038/s41574-019-0194-6CrossRefPubMed

28.

Bernard V, Young J, Chanson P, Binart N (2015) New insights in prolactin: pathological implications. Nat Rev Endocrinol 11(5):265–275. https://doi.org/10.1038/nrendo.2015.36CrossRefPubMed

29.

Cotzomi E, Stathopoulos P, Lee CS et al (2019) Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain 142(6):1598–1615. https://doi.org/10.1093/brain/awz106CrossRefPubMedPubMedCentral

30.

Vaishnav RA, Liu R, Chapman J et al (2013) Aquaporin 4 molecular mimicry and implications for neuromyelitis optica. J Neuroimmunol 260(1-2):92–98. https://doi.org/10.1016/j.jneuroim.2013.04.015CrossRefPubMedPubMedCentral

31.

Fujihara K, Bennett JL, de Seze J et al (2020) Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol(R) Neuroimmunol Neuroinflamm 7(5). https://doi.org/10.1212/NXI.0000000000000841

32.

Lahat N, Miller A, Shtiller R, Touby E (1993) Differential effects of prolactin upon activation and differentiation of human B lymphocytes. J Neuroimmunol 47(1):35–40CrossRefPubMed

33.

Dimitrov S, Lange T, Fehm HL, Born J (2004) A regulatory role of prolactin, growth hormone, and corticosteroids for human T-cell production of cytokines. Brain Behav Immun 18(4):368–374CrossRefPubMed

34.

Sodhi A, Tripathi A (2008) Prolactin and growth hormone induce differential cytokine and chemokine profile in murine peritoneal macrophages in vitro: involvement of p-38 MAP kinase, STAT3 and NF-kappaB. Cytokine 41(2):162–173. https://doi.org/10.1016/j.cyto.2007.11.007CrossRefPubMed

35.

Luo W, Fang L, Wang Z et al (2021) Hypothalamic lesions in neuromyelitis optica spectrum disorders: exploring a scoring system based on magnetic resonance imaging. Jpn J Radiol 39(7):659–668. https://doi.org/10.1007/s11604-021-01104-wCrossRefPubMed

36.

Beigneux Y, Arnulf I, Guillaume-Jugnot P et al (2020) Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 38:101869. https://doi.org/10.1016/j.msard.2019.101869CrossRefPubMed

37.

Okuma H, Matsumura K, Hatanaka Y, Saito F, Sonoo M (2014) Sudden onset of sleep due to hypothalamic lesions in neuromyelitis optica spectrum disorder positive for anti-aquaporin-4 antibody. Multiple Scler (Houndmills, Basingstoke, England) 20(10):1407–1408. https://doi.org/10.1177/1352458514540359CrossRef

38.

Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80(4):1523–1631CrossRefPubMed

39.

Szabo FK, Snyder N, Usdin TB, Hoffman GE (2010) A direct neuronal connection between the subparafascicular and ventrolateral arcuate nuclei in non-lactating female rats. Could this pathway play a role in the suckling-induced prolactin release? Endocrine 37(1):62–70. https://doi.org/10.1007/s12020-009-9266-zCrossRefPubMed

40.

Rutberg L, Fridén B, Karlsson AK (2008) Amenorrhoea in newly spinal cord injured women: an effect of hyperprolactinaemia? Spinal Cord 46(3):189–191. https://doi.org/10.1038/sj.sc.3102095CrossRefPubMed

41.

Vieira Borba V, Shoenfeld Y (2019) Prolactin, autoimmunity, and motherhood: when should women avoid breastfeeding? Clin Rheumatol 38(5):1263–1270. https://doi.org/10.1007/s10067-018-04415-yCrossRefPubMed

Titel: The relationship between plasma prolactin levels and clinical manifestations with neuromyelitis optica spectrum disorders
verfasst von: Hanchen Liu
Xianxing Zhang
Wei Chen
Yiwen Xu
Xiaoting Lin
Aiyu Lin
Publikationsdatum: 25.08.2023
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 2/2024
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07008-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Neurological research in Italy from 2020 to 2023

Bridging therapy improves functional outcomes and reduces 90-day mortality compared with direct endovascular thrombectomy in patients with acute posterior ischemic stroke: a systematic review and meta-analysis

Long-term safety and efficacy of frameless subthalamic deep brain stimulation in Parkinson’s disease

Role of sleep in neurodegeneration: the consensus report of the 5th Think Tank World Sleep Forum

Prevalence and correlates of fatigue in amyotrophic lateral sclerosis: A systematic review and meta-analysis